Since PCSK9 inhibitors have become clinically available, research into their potential as a ground‐breaking method of managing atherosclerotic cardiovascular disease (ASCVD) and lowering cardiovascular risk has gained traction [8]. Here, PCSK9 is linked to atherosclerosis.